Nrx pharmaceuticals, inc. (nasdaq: nrxp) announces advance of $5 million milestone payment from partners alvogen, inc. and lotus pharmaceutical co. ltd. (1975.tw)

Companies continue to work collaboratively to advance nrx-101 through registrational trials nrx remains eligible for an additional $324 million in development and sales milestones, as well as tiered double-digit royalties upon approval and commercialization of nrx-101. payment materially extends the company's cash runway radnor, pa.
NRXP Ratings Summary
NRXP Quant Ranking